Subscribe

Creo Medical Limited (CREO.L)

GBp14.05 -0.20 (-1.40%)
GB LSE Healthcare Medical - Devices
Address Unit 2, Creo House NP16 5UH
Chepstow, GB
CEO Craig Jonathan Gulliford
Website creomedical.com
IPO 2016-12-09
ISIN GB00BZ1BLL44

Explore sections of this company profile

Description

Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
GBp14.05 -0.20 (-1.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
768.3K
Beta
1.62
Float Shares
391.16M
Free Float %
94.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+27.47% +23.40% +19.54% -12.12% +43.14% +46.46% +5.45% -40.08% -93.09% -81.85% -81.85%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
14.05
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-1.29
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Devices: +11.2%
    +50.0% ★ Q4'25: -75.8% (vs Q2'23)
  • ✓
    EPS growth Medical - Devices: +28.5%
    +116.1% ★ Q4'25: +35.4% (vs Q2'23)
  • ✗
    FCF margin FCF growth · Medical - Devices: +30.9%
    -371.7% Q4'25: -900.0% (vs Q2'23)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    -345.0% Q4'25: -281.6% (vs Q2'23)
  • ✗
    ROIC Medical - Devices: +3.3%
    -49.6% Q4'25: -102.6% (vs Q2'23)
  • ✗
    Share dilution Medical - Devices: 0.0%
    +14.0% Q4'25: +54.9% (vs Q2'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    -0.21× Q4'25: -0.10× (vs Q2'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.62) × ERP
WACC = 94% × Ke + 6% × Kd (7.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 14.05
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
4 Rev. Ana.
4 EPS Ana. 		Dec 2027
4 Rev. Ana.
3 EPS Ana. 		Dec 2028
2 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
Revenue
13.5K
est: 302.0K (-95.5%)
9.43M
est: 9.10M (+3.7%)
25.16M
est: 25.55M (-1.5%)
27.17M
est: 27.14M (+0.1%)
30.80M
est: 30.30M (+1.7%)
4.00M
est: 31.23M (-87.2%)
6.00M
est: 6.00M (+0.0%)
9.35M
8.99M – 10.07M
+55.8% YoY
15.15M
13.99M – 17.79M
+62.0% YoY
26.90M
25.75M – 28.05M
+77.6% YoY
51.20M
48.01M – 58.25M
+90.3% YoY
EBITDA
-17.96M
est: -282.2K (-6,264.3%)
-21.77M
est: -8.50M (-156.1%)
-27.54M
est: -23.87M (-15.4%)
-27.62M
est: -25.36M (-8.9%)
-20.70M
est: -28.31M (+26.9%)
-26.10M
est: -29.18M (+10.6%)
-19.70M
est: -5.61M (-251.4%)
-8.74M
-9.41M – -8.40M
-55.8% YoY
-14.16M
-16.62M – -13.07M
-62.0% YoY
-25.14M
-26.21M – -24.06M
-77.6% YoY
-47.84M
-54.43M – -44.86M
-90.3% YoY
EBIT
-18.59M
est: -288.9K (-6,336.3%)
-23.29M
est: -8.70M (-167.7%)
-29.98M
est: -24.44M (-22.7%)
-30.60M
est: -25.96M (-17.9%)
-24.10M
est: -28.98M (+16.8%)
-28.60M
est: -29.87M (+4.3%)
-20.70M
est: -5.74M (-260.7%)
-8.94M
-9.63M – -8.60M
-55.8% YoY
-14.49M
-17.02M – -13.38M
-62.0% YoY
-25.73M
-26.83M – -24.63M
-77.6% YoY
-48.97M
-55.71M – -45.92M
-90.3% YoY
Net Income
-15.91M
est: -43.94M (+63.8%)
-20.32M
est: -49.52M (+59.0%)
-24.60M
est: -41.19M (+40.3%)
-26.94M
est: -50.91M (+47.1%)
-21.70M
est: -26.87M (+19.3%)
-28.70M
est: -22.55M (-27.3%)
5.30M
est: -13.99M (+137.9%)
-9.31M
-10.49M – -4.09M
+33.5% YoY
-1.97M
-3.52M – -424.2K
+78.8% YoY
3.46M
3.03M – 3.89M
+275.4% YoY
—
— – —
-100.0% YoY
SGA
10.24M
est: 760.5K (+1,245.9%)
15.64M
est: 22.90M (-31.7%)
26.11M
est: 64.34M (-59.4%)
27.29M
est: 68.35M (-60.1%)
40.50M
est: 76.30M (-46.9%)
30.30M
est: 78.65M (-61.5%)
22.10M
est: 15.11M (+46.3%)
23.54M
22.64M – 25.35M
+55.8% YoY
38.15M
35.22M – 44.80M
+62.0% YoY
67.74M
64.84M – 70.63M
+77.6% YoY
128.93M
120.89M – 146.68M
+90.3% YoY
EPS
-0.13
est: -0.12 (-7.0%)
-0.13
est: -0.14 (+5.1%)
-0.14
est: -0.11 (-22.9%)
-0.14
est: -0.14 (+0.8%)
-0.07
est: -0.06 (-11.6%)
-0.08
est: -0.05 (-52.3%)
0.01
est: -0.03 (+138.0%)
-0.02
-0.03 – -0.01
+48.0% YoY
0.00
-0.01 – 0.00
+74.6% YoY
0.01
0.01 – 0.01
+279.8% YoY
—
— – —
-100.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 B+ 3/5 1/5 4/5 5/5 3/5 2/5 4/5
2026-05-21 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-20 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-19 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-18 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-15 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-14 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-13 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-12 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-11 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-08 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-07 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-06 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-05 A 4/5 5/5 3/5 5/5 3/5 3/5 4/5
2026-05-01 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-30 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-29 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-28 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-27 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-24 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-23 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-21 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-20 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-17 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5
2026-04-16 A 4/5 5/5 3/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-48.12M
OE per share TTM
-0.12
Owner's Yield
-80.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
40.8%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-745.00
Shares Outstanding
412.47M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Craig Jonathan Gulliford Chief Executive Officer & Executive Director 377.2K male
David Gerard Woods Chief Commercial Officer 312.9K male
Richard John Rees Chief Financial Officer & Executive Director 264.6K male
Christopher Paul Hancock Founder & CTO 260.4K —
Phil Hales Sales & Marketing Director — male
Richard Gary Craven Secretary — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices